Ontology highlight
ABSTRACT: Purpose
Current protocols for CD19 chimeric antigen receptor-expressing T cells (CD19.CAR-T cells) require recipients to tolerate preinfusion cytoreductive chemotherapy, and the presence of sufficient target antigen on normal or malignant B cells.Patients and methods
We investigated whether additional stimulation of CD19.CAR-T cells through their native receptors can substitute for cytoreductive chemotherapy, inducing expansion and functional persistence of CD19.CAR-T even in patients in remission of B-cell acute lymphocytic leukemia. We infused a low dose of CD19.CAR-modified virus-specific T cells (CD19.CAR-VST) without prior cytoreductive chemotherapy into 8 patients after allogeneic stem cell transplant.Results
Absent virus reactivation, we saw no CD19.CAR-VST e
SUBMITTER: Lapteva N
PROVIDER: S-EPMC7062259 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature